Summary: Join Drs. Chapman, Gotto, and Kastelein as they discuss the results of AIM-HIGH and the latest CETP inhibitor clinical trials in HDL-targeted residual cardiovascular risk reduction.
Summary: Join Drs. Chapman, Gotto, and Kastelein as they discuss the results of AIM-HIGH and the latest CETP inhibitor clinical trials in HDL-targeted residual cardiovascular risk reduction.